Hebo Biopharma's B7H4x4-1BB bispecific antibody was approved for Phase I clinical trial in Australia

Harbour BioMed (stock code: 02142.
HK) announced that the Institutional Review Board (IRB) approved the application for a Phase I clinical trial of its investigational product B7H4x4-1BB bispecific antibody (HBM7008) in patients with solid tumors in Australia
.
The study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of HBM7008 in patients with solid tumors
.
HBM7008 is developed by Harbin Pharmaceutical's innovative immune cell connector HBICETM platform.
It is an innovative bispecific antibody that simultaneously targets tumor antigen B7H4 and T cell costimulatory molecule 4-1BB.
Activates T cells and produces antitumor activity
.
B7H4 is overexpressed in a variety of malignant solid tumors, including breast, non-small cell lung, ovarian, and endometrial cancers
.
Since HBM7008 has a cross-linking-dependent expression specificity for tumors and has high-efficiency immunoregulatory activity, it has shown excellent safety and strong anti-tumor efficacy in preclinical studies, especially in mouse tumor models.
Remission (CR)
.
Dr.
Xiaoxiang Chen, Chief Product Development Officer of Harbin Pharmaceuticals, said: "4-1BB is one of the most promising anti-tumor immune targets, providing new ideas for tumor treatment
.
Based on preclinical research data, we are confident in the B7H4x4-1BB bispecific antibody.
We are full of confidence in the potential of
the drug.
We will efficiently advance this clinical study to provide newer, more effective and safe treatment options for patients, so that more tumor patients can benefit from innovative therapies
.
” About HBM7008 HBM7008 is a tumor-related The bispecific antibody to the antigen B7H4x4-1BB is highly dependent on tumor-associated antigen-mediated cross-linking with T cell activation, so it has significant efficacy in T cell co-stimulation and tumor growth inhibition, while improving safety
.
HBM7008 is a fully human bispecific antibody developed based on Harbin Pharmaceutical's innovative HBICETM platform, and is currently the only bispecific antibody against these two targets in the world
.
Its unique tumor expression specificity and immunomodulatory activity are expected to produce better efficacy in patients who are PD-L1 negative or resistant to PD-1/PD-L1 immunotherapy drugs
.
With its novel biological mechanism of action and dual antibody design, it is expected to avoid the risk of hepatotoxicity that may be caused by 4-1BB
.
About Harbin Pharmaceutical Co.
, Ltd.
(stock code: 02142.
HK) is a global biopharmaceutical company focusing on the R&D and commercialization of innovative drugs in the field of oncology and immune diseases
.
The company has rapidly expanded its innovative drug R&D pipeline through independent R&D, joint development and diversified cooperation models
.
Harbour Mice®, Harpoon's own antibody technology platform, produces fully human monoclonal antibodies in dual, dual light chain (H2L2) and heavy chain only (HCAb) formats
.
The Immune Cell Engager (HBICETM) developed based on the HCAb antibody platform can achieve anti-tumor efficacy that cannot be achieved by traditional drug combination therapy
.
Harbour Mice®, together with the single B cell clone screening platform, forms Heplatin's next-generation innovative therapeutic antibody development engine
.